XORTX Therapeutics Files 6-K, Incorporates Exhibits
Ticker: XRTX · Form: 6-K · Filed: Oct 18, 2024 · CIK: 1729214
Sentiment: neutral
Topics: sec-filing, registration-statement, administrative
TL;DR
XORTX filed a 6-K, incorporating exhibits into their F-3. Standard update, no major news.
AI Summary
XORTX Therapeutics Inc. filed a Form 6-K on October 18, 2024, incorporating by reference Exhibits 5.1 and 5.2 into its existing Form F-3 Registration Statement (File No. 333-269429). The filing is for the month of October 2024 and includes information about the company's principal executive office in Calgary, Alberta, Canada.
Why It Matters
This filing updates the company's registration statement, which is crucial for potential future stock offerings or other capital-raising activities.
Risk Assessment
Risk Level: low — This is a routine administrative filing that incorporates previously disclosed information, not announcing new material events.
Key Numbers
- 001-40858 — Commission File Number (Identifies the company's filing with the SEC.)
- 333-269429 — Registration Statement File Number (References the company's existing F-3 registration statement.)
Key Players & Entities
- XORTX Therapeutics Inc. (company) — Registrant
- 001-40858 (dollar_amount) — Commission File Number
- 333-269429 (dollar_amount) — Registration Statement File Number
- October 17, 2024 (date) — Date of Signature
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K is to report information for the month of October 2024 and to incorporate by reference Exhibits 5.1 and 5.2 into XORTX Therapeutics Inc.'s existing Form F-3 Registration Statement (File No. 333-269429).
What exhibits are being incorporated by reference?
Exhibits 5.1 and 5.2 are being incorporated by reference into the company's Form F-3 Registration Statement.
What is the Commission File Number for XORTX Therapeutics Inc.?
The Commission File Number for XORTX Therapeutics Inc. is 001-40858.
Where is XORTX Therapeutics Inc.'s principal executive office located?
XORTX Therapeutics Inc.'s principal executive office is located at 3710 – 33rd Street NW Calgary, Alberta T2L 2M1 Canada.
What is the date of the signature for this filing?
The registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on October 17, 2024.
Filing Stats: 217 words · 1 min read · ~1 pages · Grade level 11.9 · Accepted 2024-10-18 06:09:53
Filing Documents
- tm2425989d3_6k.htm (6-K) — 11KB
- tm2425989d3_ex5-1.htm (EX-5.1) — 15KB
- tm2425989d3_ex5-2.htm (EX-5.2) — 15KB
- tm2425989d3_ex5-1img01.jpg (GRAPHIC) — 16KB
- tm2425989d3_ex5-1img02.jpg (GRAPHIC) — 1KB
- tm2425989d3_ex5-1img03.jpg (GRAPHIC) — 5KB
- tm2423989d3_ex5-2img001.jpg (GRAPHIC) — 14KB
- tm2423989d3_ex5-2img002.jpg (GRAPHIC) — 11KB
- 0001104659-24-109678.txt ( ) — 107KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. XORTX Therapeutics Inc. (Registrant) Date: October 17, 2024 By: /s/ Allen Davidoff Name: Allen Davidoff Title: President and Chief Executive Officer Form 6-K Exhibit Index Exhibit Number Document Description 5.1 Opinion of Fasken Martineau DuMolin LLP, regarding legality of securities being registered 5.2 Opinion of Troutman Pepper Hamilton Sanders LLP, regarding legality of securities being registered